A detailed history of Invesco Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 255,300 shares of CRNX stock, worth $14.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
255,300
Previous 181,599 40.58%
Holding current value
$14.3 Million
Previous $8.13 Million 60.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$43.83 - $54.98 $3.23 Million - $4.05 Million
73,701 Added 40.58%
255,300 $13 Million
Q2 2024

Aug 13, 2024

BUY
$42.12 - $51.91 $196,110 - $241,692
4,656 Added 2.63%
181,599 $8.13 Million
Q1 2024

May 14, 2024

BUY
$34.76 - $46.81 $177,484 - $239,011
5,106 Added 2.97%
176,943 $8.28 Million
Q4 2023

Feb 12, 2024

SELL
$25.62 - $37.07 $141,832 - $205,219
-5,536 Reduced 3.12%
171,837 $6.11 Million
Q3 2023

Nov 13, 2023

BUY
$15.97 - $30.59 $2.23 Million - $4.28 Million
139,796 Added 372.03%
177,373 $5.28 Million
Q2 2023

Aug 11, 2023

SELL
$15.73 - $23.6 $13,103 - $19,658
-833 Reduced 2.17%
37,577 $677,000
Q1 2023

May 12, 2023

BUY
$15.31 - $21.1 $308,174 - $424,721
20,129 Added 110.11%
38,410 $616,000
Q4 2022

Feb 13, 2023

SELL
$15.49 - $19.05 $5,669 - $6,972
-366 Reduced 1.96%
18,281 $334,000
Q3 2022

Nov 14, 2022

SELL
$18.11 - $22.37 $41,145 - $50,824
-2,272 Reduced 10.86%
18,647 $366,000
Q2 2022

Aug 15, 2022

BUY
$16.49 - $27.64 $25,988 - $43,560
1,576 Added 8.15%
20,919 $390,000
Q1 2022

May 16, 2022

SELL
$17.15 - $28.31 $2.93 Million - $4.84 Million
-170,892 Reduced 89.83%
19,343 $425,000
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $3.36 Million - $4.94 Million
173,734 Added 1052.87%
190,235 $5.4 Million
Q3 2021

Nov 15, 2021

BUY
$16.88 - $25.23 $47,247 - $70,618
2,799 Added 20.43%
16,501 $347,000
Q2 2021

Aug 17, 2021

BUY
$15.9 - $21.15 $217,861 - $289,797
13,702 New
13,702 $258,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $3.01B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.